Individualized Magnetic Stimulation for Post-stroke Cognitive Recovery: Optimization, Validation & Efficacy
Launched by JORD VINK ·
Trial Information
Current as of September 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new, personalized approach to help improve thinking and memory skills in people who have had a stroke. Many stroke survivors experience problems with thinking soon after their stroke, which can affect their daily lives. The study is testing a treatment called repetitive transcranial magnetic stimulation (rTMS), which uses gentle magnetic pulses to stimulate specific areas of the brain. Unlike previous studies that used the same brain targets for everyone, this trial aims to find the best brain areas to target for each person individually by first scanning brain activity during a thinking task.
The trial is looking for adults aged 65 to 74 who have had a stroke and are experiencing thinking or memory difficulties, as well as healthy volunteers for comparison. Participants will take part in brain scans and receive sessions where magnetic pulses are applied to the personalized target areas of their brain, as well as “sham” sessions where no real stimulation is given, to see how this affects their thinking abilities. The main goal is to better understand how this personalized magnetic stimulation could support cognitive recovery after stroke. The study has not started recruiting yet, but could offer a promising step toward more tailored treatments for thinking problems after stroke.
Gender
ALL
Eligibility criteria
About Jord Vink
Jord Vink is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on collaboration and ethical practices, Jord Vink partners with leading healthcare institutions and researchers to design and implement rigorous clinical trials across various therapeutic areas. Their mission is to generate high-quality data that supports the development of effective therapies, while ensuring the safety and well-being of participants. By leveraging cutting-edge methodologies and fostering a culture of transparency, Jord Vink aims to contribute significantly to the evolving landscape of healthcare and therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported